Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens

Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common mult...

Full description

Saved in:
Bibliographic Details
Published in:Antimicrobial agents and chemotherapy 2015-02, Vol.59 (2), p.1329-1333
Main Authors: Deslouches, Berthony, Steckbeck, Jonathan D, Craigo, Jodi K, Doi, Yohei, Burns, Jane L, Montelaro, Ronald C
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - pharmacology
Antimicrobial Cationic Peptides
Antimicrobial Cationic Peptides - pharmacology
Bacteria - drug effects
Colistin - pharmacology
Drug Resistance, Multiple, Bacterial
Experimental Therapeutics
Microbial Sensitivity Tests
Rifampin - pharmacology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multidrug resistance constitutes a threat to the medical achievements of the last 50 years. In this study, we demonstrated the abilities of two de novo engineered cationic antibiotic peptides (eCAPs), WLBU2 and WR12, to overcome resistance from 142 clinical isolates representing the most common multidrug-resistant (MDR) pathogens and to display a lower propensity to select for resistant bacteria in vitro compared to that with colistin and LL37. The results warrant an exploration of eCAPs for use in clinical settings.
ISSN:0066-4804
1098-6596
DOI:10.1128/aac.03937-14